What is the accuracy of pre-operative staging in identifying patients with single station N2 disease?

Résumé fourni par la source

Introduction: Stage III/N2 Non-small cell lung cancer (NSCLC) is a complex disease with multi-modality therapeutic options. UK practice emphasizes the presence of single station N2 (ssN2) vs multi-station N2 disease (msN2) to determine treatment. A pilot study in Manchester, found 34% of patients with pre-operative ssN2 disease (based on CT, PET-CT and EBUS) were upstaged at pathological sampling (Craig, C. et al. Lung cancer, v156, S23). This study aims to investigate this correlation across multiple centres. Methods: We conducted a retrospective analysis across 6 UK sites over a 5-year period (01/01/2016-31/12/2020). Data was collected from patients with T1-4N2M0 NSCLC, who had pre-operative staging (CT, PET and EBUS-TBNA) and an MDT diagnosis of ssN2, who underwent surgical resection. Clinical and pathological staging was compared to describe the diagnostic accuracy of pre-operative staging. Statistical analysis was performed on variables between the 2 groups. Results: 59 patients were recruited, 19 (32%) had pathological staging of msN2. 37% of these patients had no evidence of N2 nodes on CT but 89% had a PET stage of ssN2. In the false ssN2: 58% had nodes not sampled due to EBUS characteristics and size, 4 were due to negative EBUS sampling and 4 due to inaccessible nodes. There was no statistically significant difference in tumour sub-typing, location, size or PET-SUV between the 2 groups. Median time from EBUS to surgery was 33 days. Conclusion: In stage III-N2 disease, pre-operative staging is unreliable at distinguishing between ssN2 and msN2 when compared to pathological stage. This should provide caution for centres which rely on this distinction to define treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.